[HTML][HTML] Anti-obesity drug discovery: advances and challenges

TD Müller, M Blüher, MH Tschöp… - Nature Reviews Drug …, 2022 - nature.com
Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art

MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: a pathophysiological update

MA Nauck, DR Quast, J Wefers… - Diabetes, Obesity and …, 2021 - Wiley Online Library
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

[HTML][HTML] Glucagon-like peptide 1 (GLP-1)

TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Incretin hormones: Their role in health and disease

MA Nauck, JJ Meier - Diabetes, Obesity and Metabolism, 2018 - Wiley Online Library
Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

[HTML][HTML] GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials

MP Gilbert, RE Pratley - Frontiers in endocrinology, 2020 - frontiersin.org
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

MHA Muskiet, L Tonneijck, MM Smits… - Nature reviews …, 2017 - nature.com
The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

[HTML][HTML] Regulation of postabsorptive and postprandial glucose metabolism by insulin-dependent and insulin-independent mechanisms: an integrative approach

GD Dimitriadis, E Maratou, A Kountouri, M Board… - Nutrients, 2021 - mdpi.com
Glucose levels in blood must be constantly maintained within a tight physiological range to
sustain anabolism. Insulin regulates glucose homeostasis via its effects on glucose …

Amylin: pharmacology, physiology, and clinical potential

DL Hay, S Chen, TA Lutz, DG Parkes, JD Roth - Pharmacological reviews, 2015 - ASPET
Amylin is a pancreatic β-cell hormone that produces effects in several different organ
systems. Here, we review the literature in rodents and in humans on amylin research since …